AUCTORES
Globalize your Research
Case Report | DOI: https://doi.org/10.31579/2766-2314/029
1 Department of General Studies, Edward Waters College, Florida, USA.
2 Department of Social & Behavioral Sciences, Edward Waters College, Florida, USA.
3 Department of Criminal Justice & Forensic Sciences, Edward Waters College, Florida, USA.
4 Mathematics & Sciences, Edward Waters College, 1740 Kings Road, Jacksonville, FL 32209
*Corresponding Author: Prabir K. Mandal. Department of Mathematics & Sciences, Edward Waters College, 1658 Kings Road, Jacksonville, FL 32209.
Citation: Mandal A., Islam N., Okafor B. and Prabir K. Mandal, (2021) Screening, Prevention and Treatment of COVID-19 with Special Reference to African-Americans J, Biotechnology and Bioprocessing 2(3); DOI: 10.31579/2766-2314/029
Copyright: © 2021, Prabir K. Mandal This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: 20 February 2021 | Accepted: 02 March 2021 | Published: 08 March 2021
Keywords: CDC; COVID-19; SARS-CoV-2; Vaccine; African-Americans; mRNA; USFDA
Viruses mutate all the time, and the coronavirus that causes COVID-19 is no exception. As new variants of the COVID-19 emerge, a slew of new studies suggest that some may be able to evade immune responses triggered by a previous infection or by a vaccine. The novel variants of SARS-CoV-2 including those seen in the UK (2OI/5O1Y.V1/B.1.1.7), South Africa (2OH/5O1Y.V2/B.1.351), Brazil (P.1/2OJ/5O1Y.V3/B.1.1.248) have emerged with the concern of increased infectivity and virulence. Scientists are working to learn more about the characteristics of these strains whether they could cause more severe illness, and whether currently authorized vaccines will protect people against them. All viruses naturally mutate and evolve over time. For example, flu virus change often, which is why doctors recommend that you get a flu shot every year. Various mRNA vaccine platforms have been developed in recent years and validated in studies of immunogenicity and efficacy.
In the last 20 years, there have been three coronavirus infections. They are severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV-2. In early 2020, a new virus began generating headlines all over the world because of the unprecedented speed of its transmission. The disease caused by an infection with SARS-CoV-2 is called COVID-19 (caused by SARS-CoV-2 infection), which stands for coronavirus disease 2019. COVID-19 is a major cause of death and disability worldwide, totaling 89.4 million cases and 1.9 million deaths globally as of January 9, 2021 Coronaviruses are named for the crown-like spikes on the surfaces. Viruses constantly change through mutation, and new strains of a virus are expected to occur. Multiple strains of the virus that causes COVID-19 have been documented. There are about 23 genetic changes in this strain. In the United Kingdom (U.K.), a new but more transmissible variant called B.1.1.7 has emerged in September 2020 with an unusually large number of mutations. In South Africa, another variant called B.1.351 has emerged independently of the variant detected in the U.K. In Brazil, a variant called P.1 emerged, which contains a set of additional mutations that may affect its ability to be recognized by antibodies. The new strains also appeared in Denmark, the Netherlands, and other European countries. 54 cases of the U.K. variant had been identified in the U.S. Currently, there is no evidence that these strains cause more severe illness or increased risk of death, but it spreads up to 70% more easily. The U.K. variant has been detected in nine U.S. states viz., California, Colorado, Connecticut, Florida, Georgia, New York, Ohio, Oregon and Pennsylvania. Helix and Illumina (commercial testing companies) partnered with U.S. Centers for Disease Control and Prevention (CDC) screened more than 2 million COVID tests for signs of the variant. They forwarded 158 samples for further testing and found 51 were positive for the U.K. variant. The U.K. and South African variant have the same mutation on their spike protein called N501Y. The spike proteins on the virus rotate between open and closed positions. They can attach to doors on our cells called ACE2 receptors only when they are in their open positions.
Black Americans are more likely to be diagnosed, to be hospitalized, and to die from COVID-19. The death rate from COVID-19 has been reported to be 2-3 times higher among Black versus White individuals. Black individuals comprise 13.4% the U.S. population, yet account for more than 24% of COVID-19 deaths (CDC, 2020; Bogart et al., 2021). The impact of COVID-19 goes well beyond the viral infection itself, reflecting the dynamics of a long-standing adverse host environment, including access to limited resources (i.e., money, food, education, health care, job flexibility), making disadvantaged communities more vulnerable in the pandemic (Ferdinand and Nasser, 2020). A recent report from the Pew Research Center indicated that three out of four African Americans in their study responded that religion was important to them and nearly half of these individuals (47%) attended church weekly Bruce 2020). A study conducted by Block et al. (2020) reports that African Americans have lower than 80
There are two different types of tests – diagnostic and antibody. A diagnostic test can show if someone have an active coronavirus infection and should take steps to quarantine or isolate from others. Currently there are two types of diagnostic tests – molecular i.e., reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) that detect the virus’s genetic material and antigen tests that detect specific proteins from the virus. RT-qPCR assays being most commonly used. The technique uses liquids with the swab to extract the genetic material of the virus that may be on the swab. Then use special reagents (primers and probes), and a special machine to conduct several controlled heating and cooling cycles to convert the virus’s RNA into DNA, and then make millions of copies of the DNA. When specific probes bind to DNA, a special type of light is produced that can be seen by a special machine which indicates the test is positive results for infection with SARS-CoV-2, the virus that causes COVID-19. CRISPR-based assays provide a robust and sensitive alternative for the detection of SARS-CoV-2 genomes. These assays use common and widely available reagents and are adaptable to minimal instrumentation and infrastructure (Rauch et al., 2021). An antibody test looks for antibodies that are made by immune system in response to a threat (a specific virus like COVID-19). The antibodies can take several days/weeks to develop after an infection.
There is currently no cure for an infection with the new coronavirus. For milder illness, resting at home and taking medicine to reduce fever is often sufficient. The more severe cases require hospitalization, with treatment that might include supplemental oxygen, assisted ventilation and other supportive measures. In June 2020, preliminary results of an open-label randomized controlled trials (RCT) of dexamethasone showed that it significantly reduced critically ill COVID-19 patients receiving mechanical ventilation and, to a lesser degree, patients who need supplemental oxygen. In August 2020, plasma with antibodies from recovered COVID-19 patients (convalescent plasma therapy) showed both a prophylactic and therapeutic option. In October 2020, the U.S. Food and Drug Administration (USFDA) approved its first COVID-19 treatment with the medication, remdesivir (Veklury) as an intravenous (IV) infusion. Data from in vitro experimental studies indicated that hydroxychloroquine and chloroquine have an inhibitory effect on SARS-CoV-2. Though Lopinavir/ritonavir were not effective for preventing intubation or death in moderately ill hospitalized patients with COVID-19, but treatment with tocilizumab was effective in reducing deaths and time spent in intensive care for critically ill patients with severe COVID-19. In November 2020, under emergency use authorization (EUA) the USFDA granted monoclonal antibody medications e.g., bamlanivimab (Eli Lilly) and a combination of casirivimab-imdevimab (Regeneron Pharmaceuticals) administered via IV infusion were linked to decreased rates of hospitalization or visits to the emergency department. Colchicine (a common gout medication) and famotidine (the common antacid Pepcid) prevents COVID-19 hospitalizations. In November 2020, the USFDA also issued a EUA for the use of baricitinib in combination with remdesivir in hospitalized adults and children 2 years and older who require respiratory support. In February 2021, USFDA issued to Eli Lilly a EUA for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients who test positive for SARS-CoV-2 and who are at high risk for progressing to severe COVID-19.
Conventional vaccine approaches provide durable protection against a variety of dangerous diseases, but may not be applicable to non-infectious diseases, such as cancer. Therefore, the development of more potent and versatile vaccine platforms is urgently needed. In December 2020, the USFDA granted its first mRNA-based vaccines developed by Pfizer-BioNTech (BNT162b1) and Moderna (mRNA-1273). Pfizer and Moderna COVID-19 vaccines will work against the B.1.1.7 variant. If the messenger RNA (mRNA) vaccines end up being less effective against variants, they can quickly be reworked to target new sequences. That is a big advantage of that type of vaccine. One advantage of Moderna’s mRNA technology is its flexibility, because it is based on the virus’s genetic sequence. Developing a new vaccine against a new variant would be a matter of copying and pasting.
mRNA vaccines are a new type of vaccine to protect against infectious diseases. To trigger an immune response (to create antibodies), most vaccines put a weakened (or inactivated) germ (or disease causing pathogen) into our bodies. mRNA vaccines do not use the live virus that causes COVID-19, work by providing the genetic code for our cells to produce viral proteins. Using an appealing technique, the cells use DNA as the template to make mRNA molecules, which are then translated to build proteins. RNA vaccines work by introducing an mRNA sequence which is coded for a disease specific antigen. They do not affect or interact with our DNA in any way as mRNA never enters the nucleus of the cell, which is where our DNA is kept. When COVID-19 mRNA vaccines are inside the immune cells, the cells use them to make the spike protein piece, activating T-cells to fight infection and breaks down the mRNA (gets rid of them). There are issues to sort out, such as concerns about needing to store the vaccines in freezers-especially in the case of the Pfizer BioNTech vaccine, which needs to be kept at -700C, whereas another vaccine developed by the German company CureVac, can be stored at 50C. Vaccines from DNA-based Oxford-AstraZeneca or Johnson & Johnson need to be produced in lab-grown cells. Some scientists have suggested postponing the second shots of two-dose vaccines to make more available for people to get their first doses. The original recommended interval was 21 days between doses for the Pfizer vaccine and 28 days for the Moderna shots. Two-shot vaccinations aim for maximum benefit-the first dose primes immunological memory, and the second dose solidifies it. For both vaccines, a single dose protects about 50% (Pfizer) and 80% (Moderna).
Vaccines alone won’t be enough to bring the crisis under control. Rigorous and increased compliance with public health mitigation strategies, such as vaccination, physical distancing, use of masks, hand hygiene, good ventilation indoors, limiting gatherings of people in close proximity, isolation and self-quarantine, will be essential to limiting the spread of SARS-CoV-2 and protecting public health. High-income countries have reserved more than half of the world’s COVID-19 vaccine doses despite representing just 14% of the world’s population. Nationwide differences in the impact of COVID-19 could be explained, in part, by the national policies concerning the vaccination of children with BCG. However, clinical trials are underway to confirm this association.
As of February 3, 2021, 468,000 sequences of SARS-CoV-2 from COVID-19 cases globally have been uploaded into publicly available databases, including more than 93,000 from individuals in the U.S. The new variant could further exacerbate health disparities among communities of color. In comparison with DNA-based vaccines, mRNA vaccines can express target proteins more efficiently because of their expression in the cytoplasm without entering the nucleus. RNA based vaccines could have an impact due to their shorter manufacturing times and greater effectiveness. RNA vaccines have potential as novel therapeutic options for major diseases such as cancer. There is still a lot of work to be done before mRNA vaccines can become standard treatments. In the future, mRNA vaccine technology may allow for one vaccine to target multiple diseases. It is vitally important to continue research for the treatments to limit and cure COVID-19.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
